Kymera Therapeutics

Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kymera Therapeutics reports successful 2022, eyes growth through strategic partnerships

Kymera Therapeutics had a successful year, with promising data in multiple programs and a focus on targeted protein degradation.
The company's financial position is strong, with key goals set for 2023, including collaborations and advancing pipeline programs.
Challenges lie in program prioritization, mechanism of action clarity, and optimizing dosing strategies, while opportunities exist in partnerships and therapeutic innovation.
Overall, Kymera's innovative approach and strategic outlook position it well for growth and continued success in 2023.

Kymera Therapeutics reports solid Q1 performance and eyes clinical milestones

Kymera Therapeutics is progressing well in its pipeline development, focusing on innovative programs with broad enrollment criteria.
Financially, the company is stable with a strong cash position and a clear runway into the future.
While facing challenges in capital allocation and program development, Kymera is actively seeking opportunities for growth and collaboration.

Kymera Therapeutics reports robust earnings, advances in clinical trials

Kymera Therapeutics showcased strong financial performance, progress in clinical trials, and a patient-centric approach to drug development.
While facing challenges in clarity on certain trial aspects and partnership limitations, the company is well-positioned for growth and innovation.
Opportunities lie in expanding clinical studies, developing new INDs, and exploring additional indications for their drug portfolio.

Kymera Therapeutics achieves clinical milestones and financial stability for growth

Kymera Therapeutics has made significant progress in clinical development and financial stability, positioning the company for future growth and success.
The company's focus on genetically validated targets, degrader mechanisms, and combination therapies underscores a strategic and innovative approach to drug development.
While facing challenges in dose optimization and safety standards, Kymera has opportunities to leverage its strengths in solid tumors and immunology for therapeutic advancements.
Overall, Kymera's performance, strengths, and opportunities outweigh the challenges, indicating a promising outlook for the company's future in the biopharmaceutical industry.

Kymera Therapeutics reports robust earnings, advances oral immunology pipeline

Kymera Therapeutics is in a strong financial position with a clear runway for growth, focusing on advancing their oral immunology pipeline and strategic partnerships. They face challenges in prioritizing indications but have opportunities for collaborations and innovative therapeutic development.
The company's progress in clinical programs, including dose escalation trials and milestone achievements, reflects their commitment to advancing novel therapies and addressing unmet medical needs in inflammatory diseases, oncology, and immunology.

Kymera Therapeutics reports solid Q1 performance and eyes program expansion

Kymera Therapeutics had a strong start in 2024 with promising program updates and financial stability.
The company's focus on innovative degrader medicines and potential indication expansion positions it for future growth.
Challenges in data disclosure timing and partnership decisions require strategic navigation for sustained success.
Overall, Kymera's performance, strengths, and opportunities indicate a positive trajectory with key milestones ahead.

Kymera Therapeutics reports strong Q2 earnings and eyes CNS expansion

Kymera Therapeutics showcased strong financial performance, progress in clinical trials, and a focus on innovative drug development approaches.
While facing challenges in market competition and financial management, the company is well-positioned to capitalize on growth opportunities.
Overall, Kymera's emphasis on developing effective oral immunology drugs and exploring CNS indications sets a positive trajectory for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report fourth quarter and full year 2023 financial results on February 22, 2024, and will host a conference call at 8:30 a.m. ET.

Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22

WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference in New York, NY on February 7, 2024, at 9:30 a.m. ET.

Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference

IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data expected in first half of 2025

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offering of $275 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera sold and issued 3,884,158 shares of its common stock, which includes 1,633,663 shares sold and issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 8,640,594 shares of its common stock in the offering. The shares of common stock were sold at a public offering price of $25.25 per share and the pre-funded warrants were sold at a public offering price of $25.2499 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to Kymera from the offering were approximately $316.2 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera

Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

KYMR stock rocketed and then toppled Friday after Kymera outlined its newest immune disease drugs and tacked on a $275 million offering.

Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering

WATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $275 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,250,495 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 8,640,594 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $25.25 per share and the pre-funded warrants are being sold at a public offering price of $25.2499 per pre-funded warrants, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to Kymera from the offering are expected to be approximately $275 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera, excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters' option to purchase additional shares. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional $41.25 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the securities being sold in this offering are being offered by Kymera. The offering is expected to close on January 9, 2024, subject to the satisfaction of customary conditions.

Kymera Therapeutics Announces Pricing of $275 Million Public Offering

Company's focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential

R&D Day Highlights Kymera's Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, Ph.D., Founder, President and CEO, will provide an overview of the Company's progress and anticipated milestones for 2024.

Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024

Company to provide update on its emerging pipeline of high-value immunology programs Company to provide update on its emerging pipeline of high-value immunology programs

Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4

STAT3 Degrader KT-333 showed early signs of antitumor activity across liquid and solid tumors, including major responses in cutaneous T-cell lymphoma (CTCL) and Hodgkin's lymphoma

Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting

Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same.

Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474

Atopic Dermatitis (AD) trial is the second KT-474 Phase 2 clinical trial to begin enrolling patients this quarter following trial in Hidradenitis Suppurativa (HS)

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi

Rivian Automotive

ARM Holdings PLC

Soros Fund Management, the investment firm founded by billionaire George Soros, took new positions or bulked up on IPOs and a number of tech names during the third quarter.

Soros snaps up tech stocks in Q3, but dumps some of the biggest names, along with Rivian

KT-474 showed evidence of robust target degradation and pathway inhibition with a favorable safety profile in healthy volunteers and patients

Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine

Kymera's KT-474 shows promise in Phase I for HS and AD, balancing clinical potential with financial challenges. Despite revenue decrease, Kymera's strong current ratio and ample cash reserves provide short-term financial stability. Market sentiment is mixed, with high short interest and cautious institutional and insider activities reflecting investor skepticism.

Kymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseases

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President and CEO Jared Gollob - CMO Bruce Jacobs - CFO Conference Call Participants Brad Canino - Stifel Gospel M. Enyindah-Asonye - Morgan Stanley Marc Frahm - TD Cowen Eric Joseph - JPMorgan Srikripa Devarakonda - Truist Securities Derek Archila - Wells Fargo Chris Shibutani - Goldman Sachs Kalpit Patel - B.

Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript

Abstract released today highlights safety, pharmacodynamic and clinical response data collected through July 10, 2023 cut-off

Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting

First patient dosed in KT-474/SAR444656 (IRAK4) Phase 2 HS clinical trial, generating a $40 million milestone payment from partner Sanofi; dosing of first patient in Phase 2 AD trial expected in the fourth quarter of 2023

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

The dosing of the first patient in the Phase 2 Atopic Dermatitis (AD) clinical trial is expected later this quarter The dosing of the first patient in the Phase 2 Atopic Dermatitis (AD) clinical trial is expected later this quarter

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi

Kymera Therapeutics, Inc. (KYMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 Earnings? What You Should Know

WATERTOWN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, will report third quarter 2023 financial results on November 2, 2023, and will host a conference call at 8:00 a.m. ET that day.

Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2

Kymera Therapeutics, Inc. (KYMR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Kymera Therapeutics, Inc. (KYMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Preclinical models highlight the potential of KT-253 as a monotherapy and combined with the standard of care agent venetoclax for the treatment of Acute Myeloid Leukemia (AML)

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

Kymera Therapeutics, Inc. (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

News for Kymera Therapeutics Stock (KYMR)